Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy.
BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive symptoms created by unique psychological stressors specific to adult patients with AML undergoing high-intensity induction chemotherapy (HIC). This digital therapeutic can be used for inpatient setting during the 4-6 weeks related with HIC treatment.
Symptoms are difficult for thousands of patients diagnosed with AML each year. The advancement of innovative therapeutic approaches for the treatment of the associated distress following a diagnosis is promising for patients and addresses an unmet need.
AML is a rare type of bone marrow and blood cancer accounting for one per cent of all cancers. By 2021, it is expected that 20,240 new cases of AML will arise and 11,400 people will be died with this disease.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation for BNT200 for the treatment of Acute Myeloid Leukemia.
